Doxorubicin inhibits DNMT1, resulting in conditional apoptosis

Molecular Pharmacology

Volumn 66, Issue 6, 2004, Pages 1415-1420

  Yokochi, Tomoki ^a,b   Robertson, Keith D ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DNA; DNA METHYLTRANSFERASE 1; DOXORUBICIN; INTERCALATING AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAMMAL CELL; PLASMID; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR CELL;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; INTERCALATING AGENTS; KINETICS; RECOMBINANT PROTEINS; S-ADENOSYLMETHIONINE;

EID: 9444229369     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.002634     Document Type: Article

References (30)

1. Adams RL and Rinaldi A (1987) Effect of echinomycin on DNA methylation. FEBS Lett 215:266-268.
2. Bestor T, Laudano A, Mattaliano R, and Ingram V (1988) Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol 203:971-983.
3. Boucek RJ Jr, Miracle A, Anderson M, Engelman R, Atkinson J, and Dodd DA (1999) Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol 31:1435-1446.
4. Brana MF, Cacho M, Gradillas A, de Pascual-Teresa B, and Ramos A (2001) Intercalators as anticancer drugs. Curr Pharm Des 7:1745-1780.
5. Budihardjo I, Oliver H, Lutter M, Luo X, and Wang X (1999) Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15:269-290.
6. Carter SK (1975) Adriamycin - a review. J Natl Cancer Inst 55:1265-1274.
7. Copeland RA (2000) Enzymes, Wiley-VCH, New York.
8. Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21:5400-5413.
9. Hickman JA (1992) Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11:121-139.
10. Jackson-Grusby L, Beard C, Possemato R, Tudor M, Fambrough D, Csankovszki G, Dausman J, Lee P, Wilson C, Lander E, et al. (2001) Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet 27:31-39.
11. Jones PA and Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428.
12. Juttermann R, Li E, and Jaenisch R (1994) Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 91:11797-11801.
13. Karpf AR, Moore BC, Ririe TO, and Jones DA (2001) Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol Pharmacol 59:751-757.
14. Kiechle FL and Zhang X (2002) Apoptosis: biochemical aspects and clinical implications. Clin Chim Acta 326:27-45.
15. Kroemer G, Dallaporta B, and Resche-Rigon M (1998) The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60:619-642.
16. Kurabayashi M, Jeyaseelan R, and Kedes L (1994) Doxorubicin represses the function of the myogenic helix-loop-helix transcription factor MyoD. Involvement of Id gene induction. J Biol Chem 269:6031-6039.
17. Lenaz L and Page JA (1976) Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 3:111-120.
18. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, and Young RC (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (Wash DC) 197:165-167.
19. Pradhan S, Bacolla A, Wells RD, and Roberts RJ (1999) Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification and comparison of de novo and maintenance methylation. J Biol Chem 274:33002-33010.
20. Pratt WB, Ruddon RW, Ensminger WD, and Maybaum J (1994) The Anticancer Drugs, Oxford University Press, New York.
21. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, et al. (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (Lond) 416:552-556.
22. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, Vogelstein B, Baylin SB, and Schuebel KE (2000) CpG methylation is maintained in human cancer cells lacking DNMT1. Nature (Lond) 404:1003-1007.
23. Robertson KD (2001) DNA methylation, methyltransferases and cancer. Oncogene 20:3139-3155.
24. Ross W, Rowe T, Glisson B, Yalowich J, and Liu L (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44:5857-5860.
25. Segel IH (1993) Enzyme Kinetics, Wiley, New York.
26. Stancheva I and Meehan RR (2000) Transient depletion of xDnmt1 leads to premature gene activation in Xenopus embryos. Genes Dev 14:313-327.
27. Wallace KB (2003) Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93:105-115.
28. Yeung MC (2002) Accelerated apoptotic DNA laddering protocol. Biotechniques 33:734, 736.
29. Yoder JA, Yen RW, Vertino PM, Bestor TH, and Baylin SB (1996) New 5′ regions of the murine and human genes for DNA (cytosine-5)- methyltransferase. J Biol Chem 271:31092-31097.
30. Yokochi T and Robertson KD (2002) Preferential methylation of unmethylated DNA by mammalian de novo DNA methyltransferase Dnmt3a. J Biol Chem 277:11735-11745.